Straits Times Index
3,303.77 -10.28 (-0.31%) Nikkei
39,135.91 +66.23 (+0.17%) Hang Seng
19,253.14 -383.08 (-1.95%) FTSE 100
8,424.20 +3.94 (+0.05%) Bitcoin USD
71,261.06 +4,624.95 (+6.94%) CMC Crypto 200
1,512.66 +158.25 (+11.69%)
Equillium Inc (0FY.DU)
- Business Wire
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
LA JOLLA, Calif., May 14, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it has surpassed the interim enrollment target for the Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD). Equillium expects to deliver the results of the EQUATOR interim data review to Ono during the third quarter, which will then trigger Ono’s three-mo
- Zacks
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
Equillium (EQ) delivered earnings and revenue surprises of 52.94% and 16.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
LA JOLLA, Calif., May 09, 2024--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the first quarter 2024 and highlights in clinical development.
